Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics has announced the pricing of a public offering totaling approximately $100 million in gross proceeds, involving both common stock and pre-funded warrants1 3 6.

The offering consists of shares of common stock priced at $1.45 per share, and pre-funded warrants sold at an offering price (exact amount not specified in all reports)6 7.

All securities in the offering are being sold by Inhibikase, with an expected closing date of November 24, 2025, subject to standard closing conditions1 3.

The company has granted underwriters a 30-day option to purchase up to an additional 10,344,827 shares of common stock at the public offering price, less applicable discounts and commissions1 3.

Jefferies, BofA Securities, and Cantor are acting as joint book-running managers for the offering, with LifeSci Capital and Oppenheimer & Co. serving as co-lead managers, and H.C. Wainwright & Co. and Ladenburg Thalmann & Co. as co-managers1 3.

The funds are expected to support Inhibikase's development pipeline, including therapies targeting pulmonary arterial hypertension and related diseases4.

Inhibikase Therapeutics' stock experienced volatility following the announcement, reflecting typical market reaction to secondary offerings8.